Myconostica, Ltd.
Myconostica Ltd. is a medical diagnostics company based in Manchester UK, with operations in South Carolina, US. Myconostica develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life threatening invasive fungal infections. Myconostica aims to establish itself as a world leader in fungal diagnostics by providing a series of high quality, effective, and fast diagnostic tests, using the latest molecular technology. This allows for fast, accurate, and specific diagnosis, which in turn can reduce mortality rates and allow more cost effective treatment by reducing intensive care stays and allowing more effective and targeted use of medicines. The worldwide market for fungal tests is estimated to be in excess of US $250 million per annum with over 10 million people at risk of life threatening fungal infections each year in Europe and North America alone.
Amphion’s fully-diluted ownership stake in Myconostica was 22.14% as of 30 June 2009, valued at US $2.3 million (June 2008: US $5.8 million).
Management
John Garland - Chief Executive Officer
Dr. John Thornback - Chief Operating Officer
Spencer Kerry - Chief Financial Officer
Professor David Denning - Chief Medical Officer
Board of Directors
David Holbrook - (Chairman) MTI/UMIP Premier Fund
Professor David Denning - Chief Medical Officer, Myconostica Ltd.
John Garland - Chief Executive Officer, Myconostica Ltd.
John Jeans - Chief Operating Officer, Medical Research Council
Richard
C.E. Morgan - Chief Executive Officer, Amphion Innovations
Ed Snape - Nexus Medical Partners
John Thornback - Chief Operating Officer, Myconostica Ltd.
Jerel Whittingham - Managing Director, Amphion Innovations
